Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 5
2008 2
2009 1
2010 1
2011 2
2012 4
2013 3
2014 1
2015 2
2017 1
2018 1
2019 3
2020 3
2021 2
2022 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Lung Cancer in Malaysia.
Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Rajadurai P, et al. Among authors: tho lm. J Thorac Oncol. 2020 Mar;15(3):317-323. doi: 10.1016/j.jtho.2019.10.021. J Thorac Oncol. 2020. PMID: 32093853 Free article. No abstract available.
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL. F Smit E, et al. Among authors: tho lm. Future Oncol. 2022 Mar;18(9):1039-1054. doi: 10.2217/fon-2021-1406. Epub 2021 Dec 17. Future Oncol. 2022. PMID: 34918545 Free article.
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai P, Cheah PL, How SH, Liam CK, Annuar MAA, Omar N, Othman N, Marzuki NM, Pang YK, Bustamam RSA, Tho LM. Rajadurai P, et al. Among authors: tho lm. Lung Cancer. 2019 Oct;136:65-73. doi: 10.1016/j.lungcan.2019.08.005. Epub 2019 Aug 5. Lung Cancer. 2019. PMID: 31446227 Free article. Review.
Trastuzumab-related palmar plantar erythrodysaesthesia.
Tho LM, Bose N, Robertson L, Bhattacharya S, McClue L, Anderson L, Fraser E, Graham K, Yosef H, Lumsden G. Tho LM, et al. Clin Oncol (R Coll Radiol). 2012 Feb;24(1):80-1. doi: 10.1016/j.clon.2011.10.002. Epub 2011 Oct 22. Clin Oncol (R Coll Radiol). 2012. PMID: 22019483 No abstract available.
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia.
How SH, Liam CK, Zainal Abidin MA, Hasbullah HH, Tho LM, Ho GF, Muhamad Nor I, Pang YK, Ho KF, Thiagarajan M, Ariffin R, Samsudin A, Omar A, Tan SN, Ong CK, Soon SY, Poh ME. How SH, et al. Among authors: tho lm. Cancer Manag Res. 2022 Jun 16;14:1995-2005. doi: 10.2147/CMAR.S364713. eCollection 2022. Cancer Manag Res. 2022. PMID: 35733510 Free PMC article.
34 results